Slide
"I am a 45 year old former Ironman...
hoping to avoid a hip replacement at all costs."

- Early OA Patient
Slide
"I am 52, active...young in every way
except my hip"

- Early OA Patient
Slide
"A hip replacement at 35 is nonsense and would
mean the end of my career as a dancer."

- Early OA Patient
Slide

- Dr. Thomas Vail, University of California, San Francisco
"Orthopedic surgeons have been waiting for cartilage resurfacing technology for years. If efficacy can be shown, this technology will rapidly be adopted.”

This is an Untapped Market

People In the United States Suffer From Osteoarthritis

14-55

Age Range: Aimed at Younger Patients Suffering from OA

The Growing Hip Preservation Market is worth Billions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Our Technology?

Expertise and Innovation

Sign up for Business News

Questions

About the

Technology?

Expertise and Innovation

Sign up for Business News

News

Breakthrough Device Designation from the FDA

Breakthrough Device Designation from the FDA

  We are thrilled to announce that we just received a Breakthrough Device Designation from the United States Food and Drug Administration (FDA) for our novel hip cartilage repair technology. The intent of the Breakthrough Devices Program1 is to help patients have...

read more
October Newsletter

October Newsletter

The October issue of the CytexOrtho newsletter covers our progression toward clinical trials, discussions with the FDA, and our new CRP award from NIH! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...

read more
In WRAL Techwire

In WRAL Techwire

CytexOrtho is in the news! WRAL Techwire featured a Startup Spotlight article about CytexOrtho on Monday, August 8th, 2022.  According to WRAL: “Startup Spotlight is a regular feature in WRAL Techwire, bringing attention to promising emerging companies across the...

read more

News

Breakthrough Device Designation from the FDA

Breakthrough Device Designation from the FDA

  We are thrilled to announce that we just received a Breakthrough Device Designation from the United States Food and Drug Administration (FDA) for our novel hip cartilage repair technology. The intent of the Breakthrough Devices Program1 is to help patients have...

read more
October Newsletter

October Newsletter

The October issue of the CytexOrtho newsletter covers our progression toward clinical trials, discussions with the FDA, and our new CRP award from NIH! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...

read more
In WRAL Techwire

In WRAL Techwire

CytexOrtho is in the news! WRAL Techwire featured a Startup Spotlight article about CytexOrtho on Monday, August 8th, 2022.  According to WRAL: “Startup Spotlight is a regular feature in WRAL Techwire, bringing attention to promising emerging companies across the...

read more